MORE►
biopharma
Instil Bio Chief Medical Officer Jamie Freedman, MD, PhD [Photo: LinkedIn]
Instil Bio Appoints ‘Seasoned’ Biopharma Exec as Chief Medical Officer
by Lance Murray | Jun 5, 2025
Dallas' Instil Bio said that Jamie Freedman has extensive experience in oncology drug development and other therapeutic areas, along with a track record of leading programs through all phases of development, regulatory approval, and commercialization.
by Lance Murray |
May 8, 2025
Eric Matthews will provide strategic leadership to biopharma business development, and through his executive leadership, support Caris' expanding portfolio of biopharma partnerships, the company said.
MORE►
by Lance Murray |
Jan 2, 2025
Irving-based McKesson Corp. has finalized the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a mid-market Canadian private equity firm.
McKesson said the deal enables it to focus capital deployment and prioritize investments expanding its strategic oncology and biopharma growth platforms.
The deal, which was announced in September, closed on Dec....
MORE►
by Lance Murray |
Oct 1, 2024
McKesson said that with a scalable, flexible suite of services and an experienced leadership team, InspiroGene enables manufacturers, payers, and providers to navigate the complex CGT commercialization landscape—ensuring that "patients can access the life-changing treatments they need."
MORE►
David J. Lockhart, CEO and president of ReCode Theraputics [Photo: ReCode Theraputics]
Dallas Biopharma ReCode Therapeutics Closes $80M Series B Round to Expand Drug Pipeline for Respiratory Diseases
by Alex Edwards | Oct 21, 2021
The funding, which was co-led by Pfizer Ventures and EcoR1 Capital, will help drive ReCode's therapy programs for primary ciliary dyskinesia and cystic fibrosis into human clinical studies.
MORE►
by Alex Edwards |
Nov 18, 2020
Lantern Pharma amassed 1 billion data points on its proprietary artificial intelligence platform, which it believes is the most of any company in biotech. Now, the company is able to reduce cost, time, and risk to establish a more sustainable route in oncology drug development.
MORE►
by Amy Wolff Sorter |
Oct 2, 2017
An increasing number of companies are eyeing North Texas as a location to establish their large-scale manufacturing operations.
MORE►
